Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H McGovern

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 27, 2014
Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) studyBehzad Hajarizadeh, Bart Grady, Kimberly Page, et al.
The Journal of Infectious Diseases|August 2, 2025
Comparability of gastrointestinal microbiome and bile acid profiles in patients with first or multiply recurrent Clostridioides difficile infectionJessica A Bryant, Timothy J Straub, Darrell S Pardi, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infectionJason Grebely, Kimberly Page, Rachel Sacks-Davis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 4, 2023
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based TherapeuticCharles S Berenson, Bret Lashner, Louis Y Korman, et al.
Gastroenterology|August 9, 2020
A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative ColitisMatthew R Henn, Edward J O'Brien, Liyang Diao, et al.
Nature Medicine|January 6, 2026
The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiomeJessica A Bryant, Marin Vulić, Emily A Walsh, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 8, 2020
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 TrialBarbara H McGovern, Christopher B Ford, Matthew R Henn, et al.
JAMA Network Open|February 13, 2023
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm TrialMatthew D Sims, Sahil Khanna, Paul Feuerstadt, et al.
The New England Journal of Medicine|January 19, 2022
SER-109, an Oral Microbiome Therapy for Recurrent <i>Clostridioides difficile</i> InfectionPaul Feuerstadt, Thomas J Louie, Bret Lashner, et al.
Infectious Diseases and Therapy|August 30, 2024
Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDIColleen S Kraft, Matthew Sims, Michael Silverman, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 27, 2014
Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) studyBehzad Hajarizadeh, Bart Grady, Kimberly Page, et al.
The Journal of Infectious Diseases|August 2, 2025
Comparability of gastrointestinal microbiome and bile acid profiles in patients with first or multiply recurrent Clostridioides difficile infectionJessica A Bryant, Timothy J Straub, Darrell S Pardi, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infectionJason Grebely, Kimberly Page, Rachel Sacks-Davis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 4, 2023
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based TherapeuticCharles S Berenson, Bret Lashner, Louis Y Korman, et al.
Gastroenterology|August 9, 2020
A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative ColitisMatthew R Henn, Edward J O'Brien, Liyang Diao, et al.
Nature Medicine|January 6, 2026
The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiomeJessica A Bryant, Marin Vulić, Emily A Walsh, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 8, 2020
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 TrialBarbara H McGovern, Christopher B Ford, Matthew R Henn, et al.
JAMA Network Open|February 13, 2023
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm TrialMatthew D Sims, Sahil Khanna, Paul Feuerstadt, et al.
The New England Journal of Medicine|January 19, 2022
SER-109, an Oral Microbiome Therapy for Recurrent <i>Clostridioides difficile</i> InfectionPaul Feuerstadt, Thomas J Louie, Bret Lashner, et al.
Infectious Diseases and Therapy|August 30, 2024
Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDIColleen S Kraft, Matthew Sims, Michael Silverman, et al.
Pageof 11